Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort

Codes-Mendez,H.,Sainz,L.,Park,H. S.,Corominas,H.,Diaz-Torne,C.
DOI: https://doi.org/10.1136/rmdopen-2024-004173
2024-04-17
RMD Open
Abstract:The 2023 ACR/EULAR Classification Criteria for calcium pyrophosphate deposition (CPPD) disease were recently approved.1 These criteria used an adjusted domain scoring system including demographic, clinical and radiological characteristics, and synovial fluid crystal analysis. Their development was driven by the necessity to address diagnostic challenges arising from variable clinical presentations and the complexity of analysing synovial fluid seeking for CPP crystals, with their primary purpose being to identify patients eligible for inclusion in research studies.2 Differential diagnosis of CPPD-disease mostly involves rheumatoid arthritis (RA) for chronic-CPP crystal inflammatory arthritis, gout for acute-CPP crystal arthritis and osteoarthritis (OA) with CPPD (often identified incidentally).3 Particularly, discerning between chronic-CPP crystal arthritis and seronegative-RA can be challenging due to overlapping joint involvement, seronegativity, potential treatment responses and occasional coexistence.4–6 We performed a retrospective cross-sectional analysis within a real-world clinical setting. Our objectives were to evaluate the proportion of patients diagnosed with seronegative-RA who fulfilled the CPPD-disease classification criteria, and to identify demographic and clinical differences among ...
rheumatology
What problem does this paper attempt to address?